Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: GlobeNewswire
SAN MATEO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York at 11:00 a.m. ET / 8:00 a.m. PT on September 10, 2024; andA fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024. Webcasts of each fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with archived replays available for 90 days following the live event. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024 [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024GlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
SGMT
Earnings
- 11/14/24 - Beat
SGMT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- SGMT's page on the SEC website